The invention relates to new PI3K/AKT/m TOR inhibitors and their use for the prevention and/or the treatment of a disease selected from the group consisting of: inflammatory diseases, autoimmune diseases, neurodegenerative diseases, cancers, transplant rejection, diseases characterized by a premature aging and tuberous sclerosis.

The present invention relates to the field of dihydromyricetin extraction and purification, and in particular to a dihydromyricetin extraction and purification process. Technical problem: the dihydromyricetin extraction and purification process aims to resolve the technical problems of increased cost of subsequent impurity removing and safety risks in high-temperature centrifugation in the prior art. Technical solution: a dihydromyricetin extraction and purification process: step 1: weighing a raw material, adding an extraction solvent in an amount 5 times that of the raw material to perform reflux extraction, concentrating the filtrate to an extract, and recovering acetone; step 2: resting for crystallization for 24 hours; step 3: performing suction filtration to obtain light-green sediment underneath, and dry the sediment; step 4: adding 5%-10% activated carbon for decolorization and impurity removing; step 5: performing suction filtration; step 6: drying to obtain white powder of dihydromyricetin; and step 7: detecting a content with HPLC.

The present invention relates to the field of dihydromyricetin extraction and purification, and in particular to a dihydromyricetin extraction and purification process. Technical problem: the dihydromyricetin extraction and purification process aims to resolve the technical problems of increased cost of subsequent impurity removing and safety risks in high-temperature centrifugation in the prior art. Technical solution: a dihydromyricetin extraction and purification process: step 1: weighing a raw material, adding an extraction solvent in an amount 5 times that of the raw material to perform reflux extraction, concentrating the filtrate to an extract, and recovering acetone; step 2: resting for crystallization for 24 hours; step 3: performing suction filtration to obtain light-green sediment underneath, and dry the sediment; step 4: adding 5%-10% activated carbon for decolorization and impurity removing; step 5: performing suction filtration; step 6: drying to obtain white powder of dihydromyricetin; and step 7: detecting a content with HPLC.

The present invention relates to a group of cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof. The cannabinoid derivatives of the invention are analogues of cannabidiol (CBD). CBD is a non-psychoactive cannabinoid which has been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of the cannabinoid derivatives of the invention

The present invention relates to a group of cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof. The cannabinoid derivatives of the invention are analogues of cannabidiol (CBD). CBD is a non-psychoactive cannabinoid which has been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of the cannabinoid derivatives of the invention

Disclosed are chromane compounds, analogs thereof, and methods of their synthesis and use. The compounds may be synthesized by methods involving reductive annulations of arylidene malonates with unsaturated electrophiles using photoredox/Lewis acid cooperative catalysis. The compounds may be formulated in a pharmaceutical composition for treating one of the aforementioned diseases or disorders.

Disclosed are chromane compounds, analogs thereof, and methods of their synthesis and use. The compounds may be synthesized by methods involving reductive annulations of arylidene malonates with unsaturated electrophiles using photoredox/Lewis acid cooperative catalysis. The compounds may be formulated in a pharmaceutical composition for treating one of the aforementioned diseases or disorders.

The present invention provides cannabinoid derivatives, pharmaceutical compositions comprising same, and methods of use thereof as medicaments.

The present invention provides cannabinoid derivatives, pharmaceutical compositions comprising same, and methods of use thereof as medicaments.

The present invention relates to the field of dihydromyricetin extraction and purification, and in particular to a dihydromyricetin extraction and purification process. Technical problem: the dihydromyricetin extraction and purification process aims to resolve the technical problems of increased cost of subsequent impurity removing and safety risks in high-temperature centrifugation in the prior art. Technical solution: a dihydromyricetin extraction and purification process: step 1: weighing a raw material, adding an extraction solvent in an amount 5 times that of the raw material to perform reflux extraction, concentrating the filtrate to an extract, and recovering acetone; step 2: resting for crystallization for 24 hours; step 3: performing suction filtration to obtain light-green sediment underneath, and dry the sediment; step 4: adding 5%-10% activated carbon for decolorization and impurity removing; step 5: performing suction filtration; step 6: drying to obtain white powder of dihydromyricetin; and step 7: detecting a content with HPLC.